|

DPX-Survivac Clinical Trials

1 actively recruiting trial across 1 location

Also known as: maveropepimut-S

Pipeline

Phase 2: 1

Top Sponsors

  • ImmunoVaccine Technologies, Inc. (IMV Inc.)1

Indications

  • Relapsed Diffuse Large B Cell Lymphoma1
  • Refractory Diffuse Large B-Cell Lymphoma1
  • Cancer1

Fountain Valley, California1 trial

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Compassionate Cancer Care Medical Group

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.